Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) Gross Margin (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Gross Margin for 12 consecutive years, with 32.18% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin fell 67.0% year-over-year to 32.18%, compared with a TTM value of 37.82% through Sep 2025, down 1195.0%, and an annual FY2024 reading of 41.27%, down 992.0% over the prior year.
  • Gross Margin was 32.18% for Q3 2025 at Arcadia Biosciences, down from 43.37% in the prior quarter.
  • Across five years, Gross Margin topped out at 379.21% in Q3 2022 and bottomed at 12.95% in Q2 2021.
  • Average Gross Margin over 5 years is 49.62%, with a median of 36.98% recorded in 2023.
  • The sharpest move saw Gross Margin soared 48062bps in 2021, then crashed -34223bps in 2023.
  • Year by year, Gross Margin stood at 12.7% in 2021, then skyrocketed by 426bps to 66.76% in 2022, then grew by 15bps to 77.09% in 2023, then crashed by -59bps to 31.93% in 2024, then rose by 1bps to 32.18% in 2025.
  • Business Quant data shows Gross Margin for RKDA at 32.18% in Q3 2025, 43.37% in Q2 2025, and 43.17% in Q1 2025.